Cochlear Limited (ASX:COH) shares drop 7% on results release

The Cochlear Limited (ASX:COH) share price has tumbled lower after its FY 2018 profit fell a touch short of expectations…

| More on:

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Limited (ASX: COH) share price has sunk 7% lower this morning to $184.65 after the release of the hearing solutions company's full-year results.

For the 12 months ended June 30 Cochlear posted a net profit after tax of $245.8 million on sales revenue of $1,351 million, which was an increase of 10% and 9%, respectively, on the prior corresponding period.

Diluted earnings per share came in at 426.7 cents, compared to 389.1 cents in FY 2017. This allowed management to declare a final dividend of $1.60 per share, bringing its full-year pay-out up to $3.00 per share from $2.70 per share.

The solid top line growth was driven by an 8% increase in implant unit sales to 35,260. Units would have been up 11% year-on-year if you exclude tenders from the Chinese Central Government. The FY 2018 result includes around 1,100 Chinese Central Government tender units compared to around 1,900 in FY 2017.

The Cochlear implants segment generated revenue of $831 million for the period, up 8% on FY 2017. Whereas its Services segment grew revenue by a solid 16% year-on-year to $355.2 million and its Acoustics segment saw revenue rise just 1% in FY 2018 to $165.2 million.

Once again it was the Americas region that contributed the most to its revenue. Approximately 48% of its sales were generated there, with 35% generated in the Europe, Middle East, and Africa (EMEA) region, and the remaining 17% generated the Asia Pacific region.

The U.S. market was a key highlight during the 12 months. Sales in the U.S. grew approximately 15% in FY 2018 thanks to market growth and market share gains. Management has pointed to new product introductions and the success of awareness building initiatives for this strong performance.

Expenses grew in line with sales during the period and totalled $1,023.3 million. This was due to the sizeable increase in selling, marketing and general expenses and administration expenses offsetting improvements in its gross margin. This ultimately led to Cochlear generating $258.1 million in operating cash flow during the 12 months, down slightly on FY 2017.

Outlook.

Management expects the company's growth to continue in FY 2019. It has provided FY 2019 net profit guidance of $265 million to $275 million, up between 8% and 12% on FY 2018.

This is based largely on developed market growth continuing and the Australian dollar averaging 75 U.S. cents and 63 Euro cents for the 12 months.

Should you invest?

Although its net profit after tax fell a touch short of the Bloomberg consensus estimate of $246.9 million, I still thought this was a solid result from Cochlear that demonstrated why it is one of the highest quality companies on the Australian share market along with CSL Limited (ASX: CSL) and ResMed Inc (ASX: RMD).

In light of this, I think that today's decline could be a buying opportunity for investors that are prepared to hold onto its shares for the long-term.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Dexus, Mayne Pharma, Nufarm, and Treasury Wine shares are falling today

These shares are having a tough session on Thursday. But why?

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why James Hardie, Mayne Pharma, Nufarm, and Resimac shares are falling today

These shares are having a tough time on hump day. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Kogan, Monash IVF, OFX, and ResMed shares are falling today

Why are these shares taking a tumble today? Let's find out.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Share Fallers

Why Appen, DroneShield, Gentrack, and New Hope shares are dropping today

These shares are starting the week in the red. But why?

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Dexus, Dusk, Fletcher Building, and Paladin Energy shares are falling today

These shares are ending the week in the red. But why?

Read more »

Couple look at a bottle of wine while trying to decide what to buy.
Consumer Staples & Discretionary Shares

Treasury Wine shares: Buy, hold, or sell? Here's Macquarie's take

What is Macquarie forecasting for Treasury Wine shares amid the CEO’s unexpected exit?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Newmont, NRW, Peet, and Treasury Wine shares are dropping today

Let's find out why investors are selling down these shares on Thursday.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Aristocrat, EBR, GQG, and Insignia shares are tumbling today

These shares are having a tough time on hump day. Let's find out why.

Read more »